Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
54 hedge funds and large institutions have $11.3M invested in Asterias Biotherapeutics Inc. Series A in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 62 → 54 (-8)
15% less capital invested
Capital invested by funds: $13.3M → $11.3M (-$2M)
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $163K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$127K |
| 2 |
VF
Virtu Financial
New York
|
+$69.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$53.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29.4K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$26.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
-$988K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$194K |
| 3 |
Morgan Stanley
New York
|
-$165K |
| 4 |
ECM
Element Capital Management
New York
|
-$142K |
| 5 |
Millennium Management
New York
|
-$103K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SWP
51
Stratos Wealth Partners
Beachwood,
Ohio
| – | +$51 | +33 | New |
|
52
JP Morgan Chase
New York
| – | +$76 | +49 | New |
|
AST Hedge Fund Activity: Q3 2018 in Review
54 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q3 2018, worth a combined $11.3M — down 15% from $13.3M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of AST and 4 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $127K. The largest seller was Northeast Financial Consultants, exiting entirely with an estimated $988K sold.
- 54 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q3 2018, down from 62 in Q2 2018.
- Funds reported $11.3M of Asterias Biotherapeutics Inc. Series A stock for Q3 2018, down 15% quarter-over-quarter.
- 4 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q3 2018 and 12 closed out, a net change of -8 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q3 2018 was Renaissance Technologies, an estimated $127K added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q3 2018 was Northeast Financial Consultants, an estimated $988K sold.
Based on aggregated 13F filings for Q3 2018.